Home › Therapeutic areas › Renal

Renal (25 companies · 15 conditions)

Conditions

Companies

Ticker Company Therapeutic areas In Renal Lead stage Mkt cap Programs
ACET Adicet Bio ImmunologyNeurology+2 Rare 1 Phase 1 $26.0M 8
AKBA Akebia Therapeutics HematologyOphthalmology+2 Rare 7 Approved $111M 10
ANNX Annexon HematologyNeurology+2 Rare 1 Phase 3 $662M 6
ARDX Ardelyx GI/HepatologyRenal 1 Approved $799M 4
AUTL Autolus Therapeutics HematologyImmunology+3 Rare 1 Approved $290M 12
CABA Cabaletta Bio DermatologyImmunology+2 Rare 1 Phase 2 $220M 8
IPSC Century Therapeutics ImmunologyMetabolic+1 Rare 2 Phase 1 $249M 9
CLYM Climb Bio HematologyImmunology+1 Rare 3 Phase 2 $574M 8
CGEM Cullinan Therapeutics HematologyImmunology+2 Rare 1 NDA Submitted $602M 10
IRON Disc Medicine GI/HepatologyHematology+2 Rare 1 Phase 3 $3.49B 9
ELOX Eloxx Pharmaceuticals DermatologyRenal Rare 2 Phase 2 $48.0M 4
ETON Eton Pharmaceuticals GI/HepatologyInfectious Disease+3 Rare 1 Approved $1.84B 17
FATE Fate Therapeutics ImmunologyOncology+1 Rare 1 Phase 2 $124M 10
IONS Ionis Pharmaceuticals CardiovascularHematology+5 Rare 2 Approved $4.49B 29
JBIO Jade Biosciences ImmunologyRenal Rare 1 Phase 2 $1.07B 4
KYTX Kyverna Therapeutics ImmunologyNeurology+1 Rare 1 NDA Submitted $297M 6
MAZE Maze Therapeutics MetabolicRenal Rare 2 Phase 2 $1.80B 4
MLYS Mineralys Therapeutics CardiovascularRenal+1 1 NDA Submitted $1.28B 3
NKTX Nkarta ImmunologyNeurology+1 Rare 2 Phase 1 $89.6M 8
NVCT Nuvectis Pharma HematologyOncology+1 Rare 2 Phase 3 $660M 9
PCSA Processa Pharmaceuticals GI/HepatologyImmunology+2 Rare 2 Phase 2 $4.8M 7
SCYX Scynexis Infectious DiseaseRenal Rare 1 Approved $28.4M 5
TVTX Travere Therapeutics MetabolicRenal Rare 6 Approved $4.91B 7
UNCY Unicycive Therapeutics Renal 2 NDA Submitted $108M 2
VERA Vera Therapeutics Infectious DiseaseRenal Rare 4 Approved $1.89B 6